Stocks Health care GCTK
NASDAQ · Health careGlucotrack, Inc. (GCTK)
It posted a net loss of $15.9M. In fiscal 2025 capital spending exceeded operating cash flow by $15.3M. At June 30, 2026 it held $1.1M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about Glucotrack, Inc.
- Net worth
- Glucotrack, Inc. has a market value (market cap) of $3M at the latest share price, and shareholders' equity of -$1.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $15.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
What Glucotrack, Inc. does
Glucotrack, Inc. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker GCTK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$19.4M | $31.22 | -$15.3M |
| 2024 | n/a | -$22.6M | $4,106.00 | -$12.6M |
| 2023 | n/a | -$7.1M | $2,050.60 | n/a |
| 2022 | n/a | -$4.4M | $1,564.93 | -$3.7M |
| 2021 | n/a | -$4.1M | $1,403.04 | -$3.8M |
| 2020 | n/a | -$2.7M | $1,025.30 | -$3.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Glucotrack, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 28, 2026Material agreement8-KGlucotrack repaid its bridge notes in full and amended several warrant and note agreements to remove downward floor price adjustments.
- September 24, 2026Material agreement8-KGlucotrack priced a registered direct offering to raise approximately $3.1 million in gross proceeds.
- September 23, 2026Form 425 filing 425
- September 23, 2026
- September 18, 2026Executive or director change8-KPaul V. Goode resigned from the Glucotrack Board of Directors citing a potential conflict of interest.
- September 18, 2026IPO registration S-1
- September 14, 2026
- September 11, 2026
- September 9, 2026
- September 2, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Glucotrack, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns GCTK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| White Lion Capital LLC13G, passive | 9.99% | September 2, 2026 |
Largest institutional holders
Insiders
Questions about GCTK
What does Glucotrack, Inc. do?
Glucotrack, Inc. is a company in the Health care sector, listed on NASDAQ as GCTK. Its shares trade on NASDAQ under the ticker GCTK.
What is Glucotrack, Inc.'s net worth?
Glucotrack, Inc. has a market value (market cap) of $3M at the latest share price, and shareholders' equity of -$1.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Glucotrack, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $15.9M.
When did Glucotrack, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from September 28, 2026.
Similar companies
Compare GCTK with
Follow GCTK
Get an email when Glucotrack, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Glucotrack, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.